It has been over a year since my last Regeneron Pharmaceuticals (NASDAQ: REGN ) article , where I discussed the company's strong Q4 2023 earnings and revenue growth, thanks to blockbuster numbers from Dupixent, EYLEA HD, and Libtayo. At that time, those three products He is the leader of the investing group Compounding Healthcare . Features of the group include: Several model healthcare portfolios, a weekly newsletter, a daily watchlist, and chat for dialogue and questions. Learn more Biologics is a full-ti ...